DIA年会 | 泰格医药与您相约2018DIA美国年会

泰格医药

2018年6月24至28日美国DIA年会将在波士顿举行。这次会议延用主题是推动理念变成行动(Driving insight to action)。届时,杭州泰格医药科技股份有限公司将携旗下子公司参与本次DIA年会。[展台号:2700]

The DIA 2018 will be held during June 24-28, 2018 in Boston, USA. The topical subject of this annual meeting will still be Driving Insights to Action. Tigermed Consulting Co. will attend this meeting with its member companies [booth 2700].


医药健康行业目前正处于第四次产业革命之中。在这次产业革命中,大数据、人工智能、可穿戴技术等将慢慢融入这个行业。

Healthcare industry is now in the midst of the Fourth Industrial Revolution where big data, artificial intelligence, wearable technology, and more are poised to revolutionize healthcare.


美国DIA是个汇集了全球领先的医药企业、先进的医疗教育机构以及一些有声望的医疗研究中心。所有的会员将会齐聚波斯顿一同合作、讨论、研究并解决生物科学这一领域中全球以及部分地区正在面对的挑战。DIA组织的目标以及愿望是通过公司间的合作为全世界的医疗健康产业制定更好的体制,并为全世界的病患提供更好的、科学的医疗健康产业上的服务。

DIA is an organization which members come together to collaborate and problem-solve, discussing global and local challenges facing the life sciences field in an increasingly more complex and interconnected world. The goals and hope that DIA and all its members have is for this collaboration to result in better policies, regulations, science, research and development, and ultimately better patient outcomes worldwide.


会议时间 Time

6月24日-6月28日 

June 24-28,2018


会场地址 Address

波士顿会展中心

马里兰州波士顿夏街415号02210

Boston Convention & Exhibition Center

415 Summer Street,Boston, MA 02210


泰格展位 Booth

展位号2700

Booth2700

展位效果图

Impression drawing of the booth


展台活动 Booth Activities

常建青  政策法规事务副总裁

6月25/26日  15:00

带领新药快速进入当下的中国


Maggie Chang  

Vice President, Drug Regulatory Policy

15:00  June 25th/26th

Workshop China Regulatory Update & Practice:Impact on new Drug Development in China 

2013年加入泰格医药前,在中国外商投资企业协会药品研制和开发行业委员会(RDPAC)任科学与药政法规事务委员会总监,任职五年,主要工作领域为新药研发和注册相关的药政科学事物。十五年跨国制药企业(德国先灵、英国史克必成和美国先灵葆雅)中国子公司的药品注册和临床试验部门工作经验。

Maggie joined Tigermed in 2013, after she worked with PDPAC for 5 years as director,devoted in the drug regulatory policy advocacy area. She also had 15 year experince in dpet. of drug registration andclinial trial in China subsidiaries of multinational pharmaceutical companies,e.g. Schering AG, SmithKline Beecham and Schering-Plough.